Accessibility Menu
Burning Rock Biotech logo

Burning Rock Biotech(NASDAQ) BNR

Market Cap$81.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-96%
5 Year-95%
1 Year-1%
1 Month+7%
Premium Feature
Moneyball Superscore
52/100
$9.78
+5.73%
+0.53Today
Burning Rock Biotech last closing stock price
MetricPriceDate
Last closeUSD 9.782026-08-21
Burning Rock Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10.76%USD 8.832026-08-14
1 month+7%USD 9.142026-07-22
3 month-32.6%USD 14.512026-05-22
Year to date-51.46%USD 20.152025-12-31
1 year-0.81%USD 9.862025-08-21
3 year-32.08%USD 14.402023-08-22
5 year-95.04%USD 197.202021-08-20
Since inception-96.24%USD 246.302020-06-12

Burning Rock Biotech Financials at a Glance

Market Cap

$81.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥514.43M

Net Income (TTM)

-CN¥59.32M

EPS (TTM)

-$0.79

P/E Ratio

-11.74

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$9.78

Volume

4,630

Open

$9.40

Previous Close

$9.78

Daily Range

$9.11 - $10.25

52-Week Range

$6.79 - $41.72

Estimated Earnings Date

Sep 2, 2026

BNR News

No articles available.

BNR: Motley Fool Moneyball Superscore

52

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Burning Rock Biotech

Burning Rock Biotech Limited is a leading provider of diagnostic solutions for cancer therapy selection, headquartered in Guangzhou, China. Established in 2014, the company utilizes next-generation sequencing technology to offer a diverse range of tests aimed at guiding therapeutic decisions for various cancer types.

Products and Services
  • OncoCompass IO: A liquid biopsy test for cancer therapy selection
  • OncoScreen IO: A comprehensive pan-cancer test for tissue samples
  • ColonCore: A test assessing microsatellite instability and genetic mutations in gastrointestinal cancers
Growth Outlook
  • Strategic partnerships with major pharmaceutical companies enhance market reach
  • Increasing demand for personalized medicine drives growth in diagnostic testing
  • Expansion into new markets expected to boost revenue potential
Financial Highlights
  • Recent quarterly revenue of 107.94 million CNY, showing a strong market presence
  • Gross profit margin of 72.27% indicates effective cost management
  • Cash and cash equivalents of 446 million CNY provide a solid liquidity position
Burning Rock Biotech Limited operates in the medical diagnostics and research industry, focusing on cancer-related solutions. The company has established a robust portfolio of products that cater to the growing need for precision medicine. With a strong emphasis on research and development, Burning Rock is well-positioned to capitalize on the increasing demand for advanced diagnostic tools. The strategic collaborations with industry leaders further enhance its capabilities and market presence, making it a noteworthy player in the healthcare sector. The financial metrics indicate a solid foundation, with significant revenue generation and a healthy gross profit margin, reflecting the company's operational efficiency.
AI Generated • Aug 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

667

CEO

Yu Sheng Han, MBA

Website

www.brbiotech.com

Headquarters

Guangzhou, GD 510005, CN

BNR Financials

Key Financial Metrics (TTM)

Gross Margin

74.55%

Operating Margin

-11.37%

Net Income Margin

-11.53%

Return on Equity

-10.96%

Return on Capital

-9.48%

Return on Assets

-7.53%

Earnings Yield

-8.52%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$81.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.79M

Volume

4.63K

Avg. Volume

18.66K

Financials (TTM)

Gross Profit

CN¥383.52M

Operating Income

-CN¥58.51M

EBITDA

-CN¥23.10M

Operating Cash Flow

-CN¥34.22M

Capital Expenditure

-CN¥5.25M

Free Cash Flow

-CN¥39.47M

Cash & ST Invst.

CN¥446.00M

Total Debt

CN¥50.86M

Burning Rock Biotech Performance Analysis

Burning Rock Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 83,644,4806.2%
20232023-12-31CNY 75,855,022-9.3%
20242024-12-31CNY 71,673,625-5.5%
20252025-12-31CNY 75,060,4304.7%
Burning Rock Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3011.6%
Q32025-09-30-11.4%
Q42025-12-31-4.0%
Q12026-03-31-14.5%
Burning Rock Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -13.8817.1%
20232023-12-31CNY -9.01-35.1%
20242024-12-31CNY -4.68-48.1%
20252025-12-31CNY -0.72-84.5%
Burning Rock Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3028.0%
Q32025-09-30-73.3%
Q42025-12-315.8%
Q12026-03-31-15.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CN¥107.94M

-18.9%

Gross Profit

CN¥78.01M

-19.9%

Gross Margin

72.27%

N/A

Market Cap

$81.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$121.84K

N/A

Employees

667

N/A

Net Income

-CN¥17.47M

-29.4%

EBITDA

-CN¥17.23M

-29.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CN¥446.00M

-9.9%

Total Debt

CN¥50.86M

+20.1%

Accounts Receivable

CN¥177.21M

+0.3%

Inventory

CN¥54.29M

-17.0%

Long Term Debt

CN¥29.55M

+49.1%

Short Term Debt

CN¥21.31M

-5.4%

Return on Assets

-7.53%

N/A

Return on Invested Capital

-10.49%

N/A

Free Cash Flow

-CN¥29.30M

-24.6%

Operating Cash Flow

-CN¥29.30M

-24.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EKSOEkso Bionics Holdings, Inc.
$15.90-9.86%
AYTUAytu BioPharma, Inc.
$2.37+3.95%
PMNProMIS Neurosciences, Inc.
$14.51-2.68%
ADVBAdvanced Biomed Inc. Common Stock
$8.14-0.61%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About BNR

What is the current price of Burning Rock Biotech?

Burning Rock Biotech is trading at $9.78 per share.

What is the 52-week range for Burning Rock Biotech?

Over the past 52 weeks, Burning Rock Biotech has traded between $6.79 and $41.72.

How much debt does Burning Rock Biotech have?

As of the most recent reporting period, Burning Rock Biotech reported total debt of CN¥7.36M.

How much cash does Burning Rock Biotech have on hand?

Burning Rock Biotech reported CN¥64.96M in cash and cash equivalents in its most recent financial results.

What is Burning Rock Biotech’s dividend yield?

Burning Rock Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services